Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Anal Chem. 2011 Mar 31;83(9):3312–3318. doi: 10.1021/ac103038s

Carbon Isotopes Profiles of Human Whole Blood, Plasma, Red Blood Cells, Urine and Feces for Biological/Biomedical 14C-Accelerator Mass Spectrometry Applications

Seung-Hyun Kim †,§, Jennifer C Chuang , Peter B Kelly , Andrew J Clifford †,*
PMCID: PMC3086998  NIHMSID: NIHMS285394  PMID: 21452856

Abstract

Radiocarbon (14C) is an ideal tracer for in vivo human ADME (absorption, distribution, metabolism, elimination) and PBPK (physiological-based pharmacokinetic) studies. Living plants preferentially incorporate atmospheric 14CO2, vs 13CO2, vs 12CO2, which result in unique signature. Furthermore, plants and the food chains they support also have unique carbon isotope signatures. Humans, at the top of the food chain, consequently acquire isotopic concentrations in the tissues and body fluids depending on their dietary habits. In preparation of ADME and PBPK studies, 12 healthy subjects were recruited. The human baseline (specific to each individual and their diet) total carbon (TC) and carbon isotope 13C (δ13C) and 14C (Fm) were quantified in whole blood (WB), plasma, washed red blood cell (RBC), urine, and feces. TC (mg of C/100μL) in WB, plasma, RBC, urine, and feces were 11.0, 4.37, 7.57, 0.53, and 1.90, respectively. TC in WB, RBC, and feces was higher in men over women, P < 0.05. Mean δ13C were ranked low to high as follows, feces < WB = plasma = RBC = urine, P < 0.0001. δ13C was not affected by gender. Our analytic method shifted δ13C by only ± 1.0 ‰ ensuring our Fm measurements were accurate and precise. Mean Fm were ranked low to high as follows, plasma = urine < WB = RBC = feces, P < 0.05. Fm in feces was higher for men over women, P < 0.05. Only in WB, 14C levels (Fm) and TC were correlated with one another (r = 0.746, P < 0.01). Considering the lag time to incorporate atmospheric 14C into plant foods (vegetarian) and or then into animal foods (non-vegetarian), the measured Fm of WB in our population (recruited April 2009) was 1.0468 ± 0.0022 (mean±SD), the Fm of WB matched the (extrapolated) atmospheric Fm of 1.0477 in 2008. This study is important in presenting a procedure to determine a baseline for a study group for human ADME and PBPK studies using 14C as a tracer.

Keywords: Carbon isotopes, accelerator mass spectrometry, human blood, urine, feces

INTRODUCTION

Carbon is the fourth most abundant element (180 ppm) in the earth’s crust.1 Elemental carbon has two stable isotopes (12C, 13C) and one radioactive isotope (14C). The natural abundance of 12C is 98.89 %, 13C is 1.108 %, and 14C is 1 × 10−10 %.1 The 14C has 6 protons and 8 neutrons and is present in biomass-based carbons but not petroleum-based carbons. Therefore biomass-based versus petroleum-based compounds differ from one another in the ratios of 14C to 13C to 12C. 14C is produced in the upper atmosphere by neutron and nitrogen atom reactions (1n + 14N → 14C + 1H), and most of the 14C is stored in the oceans.1-3

14C is an ideal label/tag compared to 13C for long-term in vivo human ADME (absorption, distribution, metabolism, elimination) and PBPK (physiological-based pharmacokinetic) studies of food components, nutrients and or new drugs for the following four reasons.1,3-6 First 14C has a low natural abundance. Second, 14C has a long half-life (t1/2 = 5,730 yrs). Third 14C is stably incorporated into many natural/organic molecules and or compounds. Fourth, 14C can be measured at attomol levels of sensitivity with Accelerator Mass Spectrometry (AMS) using samples that contain a milligram or less of carbon.

AMS was originally developed and used for radiocarbon dating in geochronology, archaeology, and anthropology. Recently, AMS has found biological and biomedical applications that have already filled important gaps in quantitative understandings of the long-term in vivo human ADME and PBPK of new drugs candidates, nutrients, and preservation of food components.7-16 Furthermore, the Food and Drug Administration17 and the European Medicines Agency18 recently approved 14C (the ideal tracer) for long-term in vivo human ADME and PBPK dosing of humans with 14C-labeled compounds. The doses were to be equal to or less than 1/100th of the therapeutic level or 1/50th of the no-observed adverse effect level from rodent and non-rodent species for two weeks, these doses are now commonly referred to as microdoses.

Atmospheric levels of 14C doubled (over 1950s levels) because of nuclear weapons testing in the early 1960s whereas atmospheric levels of 12C and 13C have been relatively stable. Living plants incorporate atmospheric 14CO2, 13CO2, and 12CO2 in proportion to the natural abundance of the C-isotopes and to the extent that plants, their individual tissues, and the food chains they support discriminate against heavier C-isotopes (isotope fractionation). So the ratio of 14C/13C (that AMS measures) in living organisms reflect ambient atmospheric 14C levels, with small variation among organs, and dietary habit etc.

A search of the scientific literature concerning baseline/ambient levels of carbon isotopes and/or profiles in human fluids and tissues revealed only three citations.5,19,20 Blood plasma drawn in early Y 2004 from humans at various US locations had average Fm values of 1.086 ± 0.014.20 13C and 14C levels in bloods of humans deceased in Y 2006 had an average δ13C of −19.13 ± 1.15 and an average Fm value of 1.0607 ± 0.0069.19 14C levels (in units of Fm) in whole blood (WB), plasma, and blood clots of humans which were collected in Japan in Y 2007 averaged the Fm of 1.0814 ± 0.0838, 1.0861 ± 0.0821, and 1.1667 ± 0.0428, respectively.5 The calculated values5 were based on the carbon content of 11 % for WB, 4.4 % for plasma, and 15 % for the blood clots. Finally, we found no values for 13C and 14C levels for urine or feces from humans. Therefore, the present study reports baseline (specific to each individual and their diet) total carbon (TC) contents, 13C levels, and 14C levels in fasting WB, plasma, and red blood cell (RBC), and in urine and feces from twelve healthy humans. This report is important because it provides baseline reference values of carbon isotopes contents and profiles for human ADME and PBPK studies using high-throughput (HT)-bio-14C-AMS.

MATERIALS and METHODS

Subject Selection

Healthy, non-smoking subjects (6 men and 6 women) were participated in this study. The range of their age was 19 – 39 y and their body mass index (BMI) ranged from 18.9 – 24.7 kg/m2 (Table 1). This study was approved by the Institutional Review Board (IRB) and informed consent was obtained from all subjects. The study was conducted following Good Clinical Practice guidelines (Ver. 1989) and the ethical guidelines of the 1975 Declaration of Helsinki.

Table 1.

Characteristics of twelve human subjects that participated in the present study.

Subject Gender Age, y BMI, kg/m2 Height, cm Weight, kg Packed Cell Volume
(PCV), %
2 Female 25.0 18.9 162.6 49.9 39.9
3 Female 23.0 20.0 170.2 58.1 36.7
4 Male 22.0 23.0 180.3 74.8 38.6
5 Male 23.0 24.4 185.4 83.9 39.2
6 Female 26.0 21.0 167.6 59.0 43.6
7 Male 25.0 22.9 175.3 70.3 46.0
8 Male 39.0 22.1 188.0 78.0 44.1
9 Male 32.0 24.7 177.8 78.0 43.5
10 Male 23.0 23.1 182.9 77.1 40.2
11 Female 29.0 21.0 167.6 59.0 39.9
12 Female 39.0 19.7 170.2 57.2 39.2
13 Female 19.0 21.0 167.6 59.0 36.6
Range (highest/lowest) 2.05 1.25 1.16 1.44 1.26
Mean ± SD
Female n = 6 26.8 ± 6.8 20.3 ± 0.9a 167.6 ± 2.8a 57.0 ± 3.6a 39.3 ± 2.6a
Male n = 6 27.3 ± 6.8 23.4 ± 1.0b 181.6 ± 4.8b 77.0 ± 4.5b 41.9 ± 3.0b
Total n = 12 27.1 ± 6.5 21.8 ± 1.8 174.6 ± 8.2 67.0 ± 11.1 40.6 ± 3.0
a b

Females had lower BMI, Height, Weight, and Packed Cell Volumes than did males P < 0.05.

Sample Collections

Fasting WB was collected in Vacutainer containing K2EDTA (BD Diagnostic). Plasma and RBC were collected from one K2EDTA Vacutainer where the original total volume was marked then promptly centrifuged at 1380 × g for 15 min (Fisher Scientific Centrific model 228 centrifuge, Labequip). The plasma aliquot was extracted after centrifugation. The remaining RBC were washed twice with a phosphate buffered saline (10 mM K2HPO4, 2.7 mM KCl, and 137 mM NaCl , pH 7.4 at 25 °C) then reconstituted to the original volume with the phosphate buffered saline, mixed, and stored in small aliquot (washed RBC).

A baseline 24-h collection of urine in 2 L Urisafe containers (Fisher Scientific, Fairlawn, NJ) was obtained from each subject. A baseline feces collection was in 4-mm-thick Stomacher bags (Fisher Scientific, Fairlawn, NJ). Feces were homogenized for 2 min with methanol (1:2, feces: methanol, w/v). Only urine and feces were collected for three week in order to examine the day to day variability in carbon content in each subject. All samples were stored in − 80 °C until analyzed for TC, 13C, and 14C.

Analysis of TC, 13C, and 14C

TC contents in all samples were measured as previously described21 using a Model 1112 carbon/nitrogen elemental analyzer (Thermo Finnegan, Rodano, Italy). TC contents were expressed as mg of carbon (C)/100 μL of samples.

13C concentrations were measured as previously described22 using a Europa 20/20 isotope ratio mass spectrometer (IR-MS, Sercon Ltd., Cheshire, UK). 13C concentrations were expressed as the change (δ) per mil (‰) difference between the 13C/12C ratio in the sample and that in a known laboratory reference standard according to the following formula: δ13C = [(13C/12C of sample/13C/12C of VPDB-standard) – 1] × 103 ‰, so the 13C enrichment was expressed relative to that of a well-known laboratory reference standard (Vienna-Pee Dee Belemnite, VPDB). The measured δ13Csample values are used in the calculation of Fm reported in this study.

14C concentrations were measured as previously described.22-25 Prior to 14C measurement, all samples of interest must be converted to elemental carbon such as graphite and/or graphite-like materials25, called graphitization.24 The graphitized samples were packed into AMS target holders and 14C concentrations were measured at the center for AMS, Lawrence Livermore National Laboratory. In this report, the 14C concentrations were expressed in units of “Fraction Modern” (Fm), a sample having a Fm of 1.0 would contain 97.89 femtomole (fmol) 14C/g of C, 6.11 pico curie (pCi)/g of C or 13.56 disintegrations per minute (dpm)/g of C in that sample.3 Therefore, if a 0.025 mL aliquot of plasma contained 1 mg of C and had an Fm = 1.1, then 1.0 mL of that plasma would contain 4.3 fmol 14C/mL plasma (1.1 Fm × 97.8 fmol 14C/g of C × 0.04 g of C/mL plasma) or 0.59664 dpm/mL plasma (1.1 Fm × 13.56 dpm/g of C × 0.04 g of C/mL plasma). The measured ambient Fm varies with year of sampling. An example of a recent ambient Fm is the mean atmospheric value of 1.0599 measured at the High Alpine Research Station (Swiss Alps, 46°33′N, 7°59′E, 3450 m a.s.l.) in Y 2006.26

In the present study, AMS measures the ratios of 14C/13C in the sample of interest and in the AMS standard Oxalic acid II (OX-2, NIST 4990C). The atmospheric 14CO2 in 1950 is the defined absolute reference Fm of 1.0. The defined absolute reference 14C-radioactivity is 0.7459 that of the OX-2 14C-radioactivity. Thus 0.7459 appears in the Fm calculation.27 The Modern (time zero) is defined as 1950.

The 13C content of OX-2 (−17.8 ‰) differs from the constant atmospheric 13C content (−25 ‰) due to isotopic fractionation in the biological system used to generate the OX-2.27 Thus the adjustment (0.975/0.9822) appears in the equation below. So, the biological isotopic fractionation in the biological sample is normalized to a constant atmospheric 13C content by [0.975/(1 + δ13Csample/1000)].

In the present study, AMS measures the ratio of 14C/13C in sample of interest and 14C/13C in the OX-2 standard. The δ13Csample was measured by the IR-MS described above.

Fm=Csample14C195014={[0.9751+(δ)Csample131000]×(C14C13)sample0.7459×0.9750.9822×(C14C13)OX2}

The 14C1950 is a hypothetical atmospheric carbon-14 level in 1950 normalized to 13C of − 25 ‰. Thus Fm is the 14C ratio in the sample of interest relative to the defined standard.27

Finally, the data were analyzed using analysis of variance (ANOVA). The dependent variables were TC content; δ13C levels before graphitization; δ13C levels after graphitization; and Fm values. The independent variables were the sample types (fasting whole blood; fasting plasma; fasting washed RBC; urine; and feces) and gender of the study population. Differences among treatments were evaluated using Fisher’s Protected Least Significant Difference (PLSD). The results were presented as mean ± standard deviation (mean ± SD).

RESULTS

Table 2 shows the concentration of TC (mg of C/100μL) in WB, plasma, RBC, urine, and feces. WB, plasma, and RBC were collected at a fasting state and analyzed in duplicate. A wide subject by subject variation was observed in urine and feces that were collected over a three week period. There was a 2.39 fold difference between subjects in terms of urine carbon and a 1.64 fold difference in fecal carbon. TC content ranked from low to high as follows: urine (0.53 %) < feces (1.90 %) < plasma (4.37 %) < RBC (7.57 %) < WB (11.0 %), P < 0.0001. WB, RBC, and feces in males had a higher level of TC than females P < 0.05, while plasma and urine were not gender dependent. TC content in WB, RBC, and plasma had smaller daily differences, so 11 μL of WB, 15 μL of washed RBC, and 25 μL of plasma reliably provided one mg of C, which was needed for accurate and precise HT-bio-14C-AMS measurement.28 TC content in the washed RBC (7.57 %) was one half the content in the non-washed RBC (17 %)3 because the washed RBC was diluted with a phosphate buffered saline in the present study. Although the TC in urine and feces varied among subjects and even varied from day to day in the same subject (P < 0.0001), an aliquot of ≈ 200 μL of urine and ≈ 60 μL of fecal homogenate provided one mg of C, which was usually needed for accurate and precise HT-bio-14C-AMS measurement.28

Table 2.

The total carbon (TC) contents of whole blood (WB), plasma, red blood cell (RBC), urine, and feces from twelve human subjects.

Subject Gender TC content using elemental analyzer, mg of C/100μL
WB Plasma RBC Urine Feces
Values based on one fasting blood from each
subject, analyzed in duplicate
Values based on 24 to 32 urine and 11 to 32
feces collections, analyzed in duplicate
2 Female 10.89 4.38 7.29 0.31 ± 0.16, n = 24 1.75 ± 0.50, n = 13
3 Female 10.96 4.47 7.36 0.35 ± 0.23, n = 26 1.34 ± 0.73, n = 11
4 Male 11.33 4.34 7.63 0.59 ± 0.27, n = 28 2.20 ± 0.33, n = 15
5 Male 11.11 4.26 7.47 0.52 ± 0.26, n = 32 1.93 ± 0.49, n = 23
6 Female 10.16 4.82 7.10 0.67 ± 0.27, n = 28 1.45 ± 0.37, n = 32
7 Male 11.69 4.34 8.43 0.68 ± 0.24, n = 29 2.45 ± 0.77, n = 19
8 Male 11.56 4.09 8.18 0.53 ± 0.28, n = 28 2.51 ± 0.35, n = 17
9 Male 11.09 4.50 8.17 0.44 ± 0.19, n = 30 2.19 ± 0.42, n = 19
10 Male 11.18 4.54 7.57 0.74 ± 0.34, n = 29 1.45 ± 0.36, n = 28
11 Female 11.13 4.35 7.65 0.37 ± 0.15, n = 28 1.78 ± 0.53, n = 16
12 Female 10.19 4.14 6.87 0.42 ± 0.23, n = 28 1.58 ± 0.32, n = 24
13 Female 10.43 4.15 7.16 0.73 ± 0.31, n = 29 2.12 ± 0.66, n = 20
Range (highest/lowest) 1.15 1.24 1.18 2.39 1.64
Mean ± SD
Female n=6 10.63 ± 0.42az 4.19 ± 0.30x 7.24 ± 0.26ay 0.48 ± 0.18v 1.67 ± 0.28aw
Male n=6 11.33 ± 0.25bz 4.23 ± 0.26x 7.91 ± 0.40by 0.58 ± 0.11v 2.12 ± 0.39bw
Total n=12 10.98 ± 0.49z 4.37 ± 0.20x 7.57 ± 0.48y 0.53 ± 0.15v 1.90 ± 0.40xw

Fasting whole blood was drawn into tubes containing K2EDTA. One aliquot of whole blood was removed. Plasma was separated by centrifugation and removed, and RBC were washed twice then reconstituted. Each whole blood, plasma, and washed RBC was analyzed in duplicate.

The subjects collected 24-32 urine samples and collected 11-32 fecal samples over the three week period. All urine and feces were analyzed. The day to day variation seen in a subject and the variation between subjects were high in urine and feces.

v – z

Values with different superscripts differed from one another samples (P < 0.0001).

a – b

WB, RBC, and feces from males have a higher level of total carbon over those from females, P < 0.05.

Table 3 summarizes 13C levels (δ13C) in WB, plasma, RBC, urine, and feces before and after graphitization process. Mean δ13C values before and after graphitization were ranked from low to high as follows: feces < WB = plasma = RBC = urine, P < 0.0001. The amount of δ13C in samples before graphitization differed among subjects (P < 0.0001). Since this difference was independent of gender, dietary habits could be responsible for this variation. The correlation between TC and δ13C (for all samples) was not statistically significant.

Table 3.

The 13C levels (δ13C) of whole blood (WB), plasma, red blood cell (RBC), urine, and feces from twelve subjects. Each value is a mean of a duplicate analysis using IR-MS. Each value is based on a fasting blood, blood fractions, urine, and feces from each subject, analyzed in duplicate before and after graphitization.

Subject Gender 13C level using IR-MS, δ13C = [(13C/12C of sample)/(13C/12C of VPDB-standard) – 1] × 103
WB Plasma RBC Urine Feces
Before After Before After Before After Before After Before After
2 Female −21.27 −21.32 −21.39 −21.17 −21.43 −21.25 −21.34 −21.82 −23.18 −23.31
3 Female −19.94 −20.06 −20.20 −20.03 −20.13 −20.09 −21.15 −21.63 −24.52 −24.63
4 Male −19.13 −19.37 −19.56 −19.38 −19.23 −19.22 −20.11 −20.84 −21.61 −22.06
5 Male −19.09 −19.23 −19.44 −19.25 −19.21 −19.16 −19.17 −19.90 −21.81 −22.35
6 Female −20.04 −20.21 −20.36 −20.25 −20.06 −20.06 −19.66 −20.75 −23.36 −23.57
7 Male −20.25 −20.41 −20.59 −20.38 −20.40 −20.36 −20.81 −21.08 −23.43 −23.86
8 Male −20.24 −20.46 −20.55 −20.37 −20.39 −20.38 −21.02 −21.67 −25.09 −25.41
9 Male −20.30 −20.65 −20.83 −20.73 −20.20 −20.34 −21.05 −21.70 −24.15 −24.34
10 Male −18.74 −18.98 −18.96 −18.86 −18.91 −18.97 −18.88 −19.56 −21.91 −22.31
11 Female −19.91 −20.18 −20.30 −20.20 −19.90 −19.99 −22.47 −23.34 −25.07 −25.29
12 Female −19.77 −20.13 −20.01 −19.88 −19.98 −20.06 −20.74 −20.98 −24.63 −24.97
13 Female −20.37 −20.64 −20.78 −20.75 −20.24 −20.37 −20.54 −21.28 −24.24 −24.39
Means ± SD
Before n=12 −19.92 ± 0.68y −20.25 ± 0.67y −20.01 ± 0.67y −20.58 ± 1.00y −23.58 ± 1.25x
After n=12 −20.14 ± 0.67y −20.10 ± 0.67y −20.02 ± 0.64y −21.21 ± 0.97y −23.87 ±1.17x
Total n=24 −20.03 ± 0.67y −20.18 ± 0.66y −20.01 ± 0.64y −20.90 ± 1.02y −23.73 ± 1.20x
Regression y=0.97x –0.91,
R2=0.98
y=0.99x – 0.01,
R2=0.99
y=0.95x – 1.04,
R2=0.98
y=0.95x – 1.71,
R2=0.94
y=0.93x – 1.99,
R2=0.98

The regression was indicated to the difference of δ13C between before graphitization and after graphitization compared to the line of identity (y=x, R2 =1).

x – y

Feces had a lower δ13C value than all other samples (P < 0.0001), irrespective of whether the feces were before or after graphitization. Gender differences were not significant to all samples, P > 0.05.

After graphitization, our analytic method shifted δ13C (up or down from baseline) by only 1.0 ‰ ensuring our Fm measurements were accurate and precise. The regression analysis of δ13C before and after graphitization showed a δ13C of urine was slightly less well fitted (r2 = 0.94) against the line of identity (y = x, r2 = 1.0) than was WB (r2 = 0.98), RBC (r2 = 0.98), plasma (r2 = 0.99), and feces (r2 = 0.98). Variations in the graphitization yield (81 ± 17 %) caused by other components like sodium or amines in urine may have contributed to the lowered r2 value in urine. Regardless of the observed δ13C shift in urine, the accuracy and precision of 14C-bio-AMS measurement was not affected.

Table 4 shows the correlation of δ13C between WB, RBC, plasma, urine, and feces prior to graphitization only. Any isotopic fractionation effect during the graphitization was eliminated for the correlation analysis. Blood and blood fractions (WB, plasma, and RBC) were highly correlated with one another (r = 0.95 – 0.99, P < 0.0001), but not with urine (r = 0.63 – 0.66, P < 0.001) nor with feces (r = 0.53 – 0.57, P < 0.01). Feces was more highly correlated with urine (r = 0.77, P < 0.0001) than blood and blood fractions (WB, RBC, plasma). Differences in δ13C between WB, plasma, RBC, urine, and feces could be due to different metabolic system, turnover system/time, etc. in human.

Table 4.

Correlation matrix of 13C levels (δ13C) in whole blood (WB), plasma, red blood cell (RBC), urine, and feces collected from twelve human subjects.

WB Plasma RBC Urine Feces
WB graphic file with name nihms-285394-t0002.jpg
Plasma
RBC
Urine
Feces

ns non-significant,

*

5 % level,

**

1 % level,

***

0.1 % level,

****

0.01 % level,

*****

< 0.0001 % level

Figure 1 shows a bomb curve adopted from Levin and Kromer (2004)29 and Levin et al. (2008).26 The bomb curve (insert, Figure 4) showed the atmospheric 14C level from Y 1959 to 2006 calendar years. The enlarged bomb curve shows the atmospheric 14C level from Y 1991 to 2006 calendar years (red rectangle area in the insert). The atmospheric CO2 kinetics was a complex process, and using the bomb curve to extrapolate the present atmospheric 14C level was not straight forward. In summary, fitting the full dataset from the peak at Y 1963 to 2006 calendar year, the second-order polynomial extrapolation overestimated contemporary atmospheric 14C level, while a linear extrapolation underestimated it. The present study used the dataset that included the period Y 1991 to 2006 only. The regression analysis (exponential, second-order polynomial, and linear regression) showed no difference between the regression methods for the time period of interest. The present study used a linear regression to extrapolate atmospheric 14C level from 2007 to 2010 calendar years. The mean atmospheric 14C measured in 2006 was 1.0599 Fm. Mean atmospheric 14C extrapolated was 1.0477 Fm in 2008 and 1.0420 Fm in 2009. The estimated atmospheric 14C concentration was then compared with 14C level in WB, plasma, RBC, urine, and feces that were collected in April 2009 as seen in Table 5.

Figure 1.

Figure 1

The bomb curve shows the change of atmospheric 14C level from Y 1959 to 2006. The bomb curve (insert) was adopted from data of Levin and Kromer (2004)29 and Levin et al (2008).26 The enlarged bomb curve shows the 14C level in atmosphere from Y 1991 to 2006. The atmospheric 14C level was extrapolated up to the Y 2010 with a linear regression fit.

Table 5.

The 14C levels (Fm) of whole blood (WB), plasma, red blood cell (RBC), urine, and feces from twelve subjects. Each value is a mean of a duplicate analysis using 14C-AMS.

Subject Gender 1.0 Fm = 97.8 fmol 14C/g of C = 6.11 pCi/g of C = 13.56 dpm/g of C
WB Plasma RBC Urine Feces
Each value is based on a fasting blood, blood fractions, urine, and feces from each subject,
analyzed in duplicate after graphitization
2 Female 1.0502 1.0452 1.0519 1.0503 1.0476
3 Female 1.0573 1.0399 1.0564 1.0499 1.0582
4 Male 1.0433 1.0333 1.0606 0.9376 1.0515
5 Male 1.0384 1.0416 1.0559 1.0206 1.0553
6 Female 1.0380 1.0286 1.0672 1.0208 1.0503
7 Male 1.0414 1.0452 1.0755 1.0415 1.0653
8 Male 1.0481 1.0269 1.0686 1.0468 1.0587
9 Male 1.0389 1.0247 1.0588 1.0362 1.0651
10 Male 1.0504 1.0323 1.0561 1.0442 1.0590
11 Female 1.0377 1.0278 1.0552 1.0634 1.0511
12 Female 1.0464 1.0281 1.0565 1.0412 1.0436
13 Female 1.0713 1.0261 1.0536 1.0135 1.0439
Range (highest/lowest) 1.0324 1.0200 1.0224 1.1202 1.0208
Means ± SD
Female n = 6 1.0502 ± 0.0128y 1.0326 ± 0.0079x 1.0568 ± 0.0054y 1.0399 ± 0.0191x 1.0491 ± 0.0054ay
Male n = 6 1.0434 ± 0.0049y 1.0340 ± 0.0080x 1.0626 ± 0.0078y 1.0212 ± 0.0420x 1.0592 ± 0.0054by
Total n = 12 1.0468 ± 0.0099y 1.0333 ± 0.0076x 1.0597 ± 0.0071y 1.0305 ± 0.0326x 1.0541 ± 0.0074y
x y

Average Fm values of plasma and urine were lower than those of WB, RBC, and feces (P < 0.05).

a b

Average Fm value of feces was higher for men over women (P < 0.05).

Table 5 shows the mean Fm in WB, plasma, RBC, urine, and feces. The Fm ranking from low to high was: plasma = urine < WB = RBC = feces, with P < 0.05. Individual variation in Fm of WB, plasma, RBC, urine, and feces was observed (P < 0.05), whereas the Fm of feces was only higher in men than women, P < 0.05. In addition, 14C levels (Fm) and TC were highly correlated only in WB (r = 0.746, P < 0.01). Considering the lag time to incorporate atmospheric 14C into plant foods (vegetarian) then into meat supply (non-vegetarian), the measured Fm of WB in our population (recruited April 2009) was 1.0468 ± 0.0022 (mean±SD). This matched the extrapolated atmospheric Fm of 1.0477 in 2008.26,29 For the same subjects, the measured Fm (1.0320) of plasma was similar to the atmospheric 14C level (1.0363 Fm) in 2010. In contrast, the measured Fm (1.0597) of RBC was matched to the mean atmospheric 14C level (1.0599 Fm) measured in 2006.

DISCUSSION

Elemental carbon consisted of three natural isotopes (12C, 13C, 14C), and twelve human-made isotopes (8C – 22C). Among various carbon isotopes, 11C, 13C, and 14C are the most popular isotopes for in vivo tracer studies in human and/or non-human models. Generally, 11C was measured by positron emission tomography (PET), 13C by conventional MS/isotopic ratio MS (IRMS), and 14C by AMS (/or decay counter).

Using MS (/or IRMS) for 13C avoids the radiation exposure and the cost of disposing radioactive waste.30 The MS (/or IRMS) also measures a ratio of 13C-tracer and tracee, and can also determine metabolites profiles, simultaneously. However, due to 13C detection limit of MS (/or IRMS), 13C-MS applications need to administer relatively large amounts of 13C-labeled compounds which led to a non-steady-state condition in vivo in human. In contrast, although the PET or AMS can measure very small amounts of 11C or 14C with only one microdosing, administration of 11C and 14C to human are limited because of human health caused by radiation exposure.

13C level in humans or animals varied with dietary habits (vegetarian, semi-vegetarian, and non-vegetarian) and dietary source (C3 plants vs. C4 plants, terrestrial-based sources vs. marine-based sources, etc.). In the present study, differences in the δ13C values in WB, plasma, RBC, urine, and feces were statistically significant (P < 0.0001). Furthermore, δ13C in WB, plasma, RBC, urine, and feces were also statistically differed between subjects, suggesting that subjects in our population consumed food from different dietary sources and had different dietary habits. For example, the δ13C values of subjects 6 and 7 in the present study were similar to one another in that their menu included moose meat almost daily. The δ13C values of subjects 4, 5, and 10 were similar to one another in that their menu was a mix (burrito, pizza, beer, soda etc.). Finally, subject 11 consumed Spanish wine on a daily basis, and for this subject the wine might account for the lower δ13C values in urine and feces.

In general, persons who ate marine-based foods or C4 plants like corn reflected higher δ13C values than those (δ13C) of persons with diets based on C3 plant-based foods.19 A prior study31 reported that elders who lived in Southwest Alaska had lower 13C level in RBC compared to 13C level of the younger population that lived at same region. This difference was from different dietary habits/sources between the elder population (more intake of marine-based foods) and younger population (more intake of certain marker foods).31 Furthermore, dietary protein source was also affected to 13C level in human hair protein, and omnivores had higher 13C level than vegetarians.32 Thus, individuals who participated in this study might consume more terrestrial-based C3 plants, meat, or etc. instead of the consumption of C4 plants or marine-based foods. The δ13C of feces strongly reflected 13C levels of dietary sources compared to those of WB, plasma, RBC, and urine, because of its direct tie to dietary intake.

The applications of 11C-PET and 14C-AMS have greatly improved ADME, PK, and mass balance studies of nutrients, biopharmaceuticals, and drug (/or candidates) in vivo in human. Prior to development of AMS, 14C applications in vivo in humans were limited due to potential of the high radiation exposure caused by a requirement for large 14C dose. Recent developments of high accuracy, precision, and sensitivity of PET and AMS have led to an increased use of 11C-PET and 14C-AMS applications. Significantly, 14C-AMS has been applied to long-term tracer studies in vivo in humans with only one time microdosing.

The 14C level in living creatures reflects the atmospheric input of carbon in the form of CO2 through photosynthesis into the food chain. Nydal et al. (1971)33 reported a good agreement in 14C level between human blood and human hair. 14C level in human blood plasma which was collected in various US areas in early Y 2004 was 1.086 ± 0.014 Fm. And, natural 14C level in plants and animals was ≈ 1.075 Fm in Y 2005. These 14C values were also well matched to the 14C levels in the atmosphere at the same time.20

The 14C level in the atmosphere decreased exponentially (mean life ≈ 16 yrs) since atmospheric bomb tests were discontinued.34 The 14C level in the atmosphere slowly declined for the past 20 years at an average rate ≈ 0.0061 Fm per year. In general, extrapolation using a linear regression fit underestimated the 14C level in the atmosphere, while a second-order polynomial regression slightly overestimated the 14C level.19 The atmospheric 14C level in Y 2009 was extrapolated to 1.0420 Fm with a linear regression fit, when the present study truncated the dataset to include only Y 1991 to 2006.26,29

The 14C level differed between atmosphere and human or animal (organs/tissues) because of their lag time (i.e. 1.1 year for blood, 1.8 year for lung, much greater time for collagen within cartilage) caused by tissue turnover (i.e. life-time of RBC: 120 days) and food dietary issues.34-38 For example, 14C level in herbivores show a slight delay compared to that of atmosphere owing to the fast turnover time of their primary carbon source. In contrast, 14C level in humans or animals (omnivores or carnivores) further delayed compared to that of atmosphere because of longer turnover time of their carbon source.34 Therefore, 14C level of human blood collected in Y 2009 was close to that (1.0477 Fm) in atmosphere in Y 2008. Of course, 14C level of humans was also reflected by 14C level in dietary sources at cultivation/harvest year.

In the present study, the mean 14C level in WB, RBC, plasma, urine, and feces showed statistically significant differences (P < 0.05). The 14C level in the WB matched the atmospheric level in Y 2008. This was consistent with a lag time of 14C level between atmosphere and human blood. Some subjects had 14C levels (in plasma, RBC, urine, and feces) that were slightly higher or slightly lower than the expected during Y 2008 to 2009 calendar years, these differences could be accounted for by human to human variations caused by different dietary habit/sources, delay time, tissue turnover, some combinations of the above, and others. Our results were also consistent with a prior report38 which reported that an individual’s diet can play as an important role in establishing radiocarbon levels in vivo in human.

In conclusion, the content of carbon isotopes in human WB, RBC, plasma, urine, and feces was affected by dietary source/habit of each subject in our population. In the present study, TC in human’s WB, plasma, RBC, urine, and feces ranged from 0.53 to 11.0 mg of C/100 μL. 13C level (δ13C) in human’s WB, plasma, RBC, urine, and feces ranged from −23.58 to −19.92 ‰, and 14C level (Fm) in human’s WB, RBC, plasma, urine, and feces also varied from 1.0320 to 1.0597 Fm. TC content in WB, RBC, and feces had gender effect, P < 0.05. And there was no gender effec on 13C levels in the samples, however there was a gender effect in 14C levels (Fm) only in the feces (P < 0.05). Thus the observed gender effect is probably related to diet. In addition, TC content was correlated with 14C levels (Fm) only in WB (r = 0.746, P < 0.01). Therefore, accurate and precise HT- bio-14C-AMS measurements would require baseline TC, 13C, and 14C levels in human samples prior to the 14C tracer study in vivo in human.

Finally, this report is important because it provides baseline reference values of carbon isotopes contents and profiles, which are individual and diet specific for human ADME and PBPK studies using high-throughput (HT)-bio-14C-AMS.

ACKNOWLEDGEMENTS

The authors thank the reviewers for their perceptive and helpful comments. This work was supported by NIH DK-078001, DK-081551, DK-45939, DK-48307, and the USDA Regional Research W-2002 from the California Agricultural Experiment Station. Aspects of this work were performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under contract DE-AC52-07NA27344 and NIH National Center for Research Resources Grant RR13461. This publication was made possible by Grant Number UL1 RR024146 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp.”

LITERATURE CITED

  • (1).Pierson HO. Handbook of Carbon, Graphite, Diamond, and Fullerenes, Processing, Properties and Applications. Noyes Publications; New York: 1993. [Google Scholar]
  • (2).Salehpour M, Possnert G, Bryhni H. Anal. Chem. 2008;80:3515–3521. doi: 10.1021/ac800174j. [DOI] [PubMed] [Google Scholar]
  • (3).Vogel JS, Love AH. Methods in Enzymology. 2005;402:402–422. doi: 10.1016/S0076-6879(05)02013-6. [DOI] [PubMed] [Google Scholar]
  • (4).Tuniz C, Bird JR, Fink D, Herzog GF. Accelerator mass spectrometry: Ultrasensitive analysis for global science. CRC Press; New York: 1998. [Google Scholar]
  • (5).Minamimoto R, Hambabe Y, Miyaoka T, Hara T, Yoshida K, Oka T, Inoue T. Ann Nucl Med. 2008;22:883–889. doi: 10.1007/s12149-008-0200-x. [DOI] [PubMed] [Google Scholar]
  • (6).Vogel JS, Turteltaub KW. Mathematical Modeling in Experimental Medicine and Biology. Vol. 445. Plenum Press; New York: 1998. pp. 397–410. [DOI] [PubMed] [Google Scholar]
  • (7).Brown K, Tompkins EM, White INH. Mass Spectrometry Reviews. 2006;25:127–145. doi: 10.1002/mas.20059. [DOI] [PubMed] [Google Scholar]
  • (8).Turteltaub KW, Felton JS, Gledhill BL, Vogel JS, Southon JR, Caffee MW, Finkle RC, Nelson DE, Proctor ID, Davis JC. Proc. Natl. Acad. Sci. 1990;87:5288–5292. doi: 10.1073/pnas.87.14.5288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (9).Ho CC, de Moura FF, Kim SH, Burri BJ, Clifford AJ. Journal of Nutrition. 2009;139:1480–1486. doi: 10.3945/jn.109.105114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (10).Ho CC, de Moura FF, Kim SH, Clifford AJ. Am. J. Clin. Nutr. 2007;85:770–777. doi: 10.1093/ajcn/85.3.770. [DOI] [PubMed] [Google Scholar]
  • (11).Clifford AJ, de Moura FF, Ho CC, Chuang JC, Follett J, Fadel JG, Novotny JA. Am. J. Clin. Nutr. 2006;84:1430–1441. doi: 10.1093/ajcn/84.6.1430. [DOI] [PubMed] [Google Scholar]
  • (12).Garner RC, G. L. Br. J. Clin. Pharmacol. 2006;61:367–370. doi: 10.1111/j.1365-2125.2006.02575.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (13).Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC. Clinical Phamacology and Therapeutics. 2006;80:203–215. doi: 10.1016/j.clpt.2006.05.008. [DOI] [PubMed] [Google Scholar]
  • (14).de Moura FF, Ho CC, Getachew G, Hickenbottom S, Clifford AJ. Lipids. 2005;40:1069–1073. doi: 10.1007/s11745-005-1471-4. [DOI] [PubMed] [Google Scholar]
  • (15).Lin Y, Dueker SR, Follett JR, Fadel JG, Arjomand A, Schneider PD, Miller JW, Green R, Buchholz BA, Vogel JS, Phair RD, Clifford AJ. Am. J. Clin. Nutr. 2004;80:680–691. doi: 10.1093/ajcn/80.3.680. [DOI] [PubMed] [Google Scholar]
  • (16).Vuong LT, Ruckle JL, Blood AB, Reid MJ, Wasnich RD, Synal H-A, Dueker SR. J Pharmaceutical Sci. 2008;97:2833–2843. doi: 10.1002/jps.21160. [DOI] [PubMed] [Google Scholar]
  • (17).US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Guidance for industry, investigators and reviewers, exploratory IND studies. Jan 12, 2006.
  • (18).The European Agency for the Evaluation of Medical products. Evaluation of Medicines for Human Use (EMEA) Committee for Proprietary Medicinal Products (CPMP) Position paper on non-clinical safety studies to support clinical trials with a single microdose, CPMP/SWP/2599/02. revised edition: CPMP/SWP/2599/02/Rev 1. London: Jan 23, 2003. London, 23 June 2004. [Google Scholar]
  • (19).Hodgins GWL. Measuring atomic bomb-derived 14C levels in human remains to determine Year of Birth and/or Year of Death. The final research report by NCJRS (Award Number: 2005-IJ-CX-K013) 2009.
  • (20).Vogel JS. Bio Techniques. 2005;38:S25–S29. [Google Scholar]
  • (21).Pella E. Am Lab. 1990;22:116–125. [Google Scholar]
  • (22).Kim SH, Kelly PB, Clifford AJ. Anal. Chem. 2009;81:5949–5954. doi: 10.1021/ac900406r. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (23).Getachew G, Kim SH, Burri BJ, Kelly PB, Haack KW, Ognibene TJ, Buchholz BA, Vogel JS, Modrow J, Clifford AJ. Radiocarbon. 2006;48:325–336. [Google Scholar]
  • (24).Kim SH, Kelly PB, Clifford AJ. Anal. Chem. 2008;80:7651–7660. doi: 10.1021/ac801226g. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (25).Kim SH, Kelly PB, Clifford AJ. Anal. Chem. 2008;80:7661–7669. doi: 10.1021/ac801228t. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (26).Levin I, Hammer S, Kromer B, Meinhardt F. Science of the Total Environment. 2008;391:211–216. doi: 10.1016/j.scitotenv.2007.10.019. [DOI] [PubMed] [Google Scholar]
  • (27).Donahue DJ, Linick TW, Jull AJT. Radiocarbon. 1990;32:135–142. [Google Scholar]
  • (28).Ognibene TJ, Bench G, Brown TA, Peaslee GF, Vogel JS. Int. J. Mass Spec. 2002;218:255–264. [Google Scholar]
  • (29).Levin I, Kromer B. Radiocarbon. 2004;46:1261–1272. [Google Scholar]
  • (30).Dueker SR, Jones AD, Clifford AJ. In: In Mathematical Modeling in Experimental Nutrition AEMB. Clifford AJ, Muller H-G, editors. Plenum Press; New York: 1998. pp. 363–378. [Google Scholar]
  • (31).Wilkinson MJ, Yai Y, O’Brien DM. International Journal of Circumpolar Health. 2007;66:31–41. doi: 10.3402/ijch.v66i1.18222. [DOI] [PubMed] [Google Scholar]
  • (32).Petzke KJ, Boeing H, Metges CC. Rapid Communications in Mass Spectrometry. 2005;19:1392–1400. doi: 10.1002/rcm.1925. [DOI] [PubMed] [Google Scholar]
  • (33).Nydal R, Lov seth K, Syrstad O. Nature. 1971;232:418–421. doi: 10.1038/232418a0. [DOI] [PubMed] [Google Scholar]
  • (34).Ubelaker DH, Buchholz BA. Forensic Science Communications. 2006;8:1–12. [Google Scholar]
  • (35).Broecker WS, Schulert A, Olson EA. Science. 1959;130:331–332. doi: 10.1126/science.130.3371.331-a. [DOI] [PubMed] [Google Scholar]
  • (36).Buchholz BA, Arjomans A, Dueker SR, Schneider PD, Clifford AJ. Analytical Biochemistry. 1999;269:348–352. doi: 10.1006/abio.1999.4041. [DOI] [PubMed] [Google Scholar]
  • (37).Libby WF, Berger R, Mead JF, Alexander GV, Ross JF. Science. 1964;146:1170–1172. doi: 10.1126/science.146.3648.1170. [DOI] [PubMed] [Google Scholar]
  • (38).Harkness DD, Walton A. Nature. 1969;223:1216–1218. doi: 10.1038/2231216a0. [DOI] [PubMed] [Google Scholar]

RESOURCES